Latest news with #EliLily
The Independent
2 days ago
- Health
- The Independent
Mounjaro weight-loss drug price to almost triple in UK after Trump complaint
The price of popular weight-loss jab Mounjaro will nearly triple after the US -owned company equalised costs in markets across the globe. A month's supply of the highest doses of the ' King Kong ' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. Last month, he reportedly wrote to the leaders of pharmaceutical companies, including Eli Lilly, asking them to match US prescription drug prices with what is paid overseas. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price " significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
Yahoo
2 days ago
- Health
- Yahoo
Mounjaro weight-loss drug price to almost triple in UK
The price of popular weight-loss jab Mounjaro will nearly triple after the US-owned company equalised costs in markets across the globe. A month's supply of the highest doses of the 'King Kong' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The NHS said the price increase would not affect its commissioning of the medicine for people with obesity and type 2 diabetes. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
The Independent
2 days ago
- Health
- The Independent
Mounjaro weight-loss drug price to almost triple in UK
The price of popular weight-loss jab Mounjaro will nearly triple after the US -owned company equalised costs in markets across the globe. A month's supply of the highest doses of the ' King Kong ' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The NHS said the price increase would not affect its commissioning of the medicine for people with obesity and type 2 diabetes. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price " significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
Yahoo
23-06-2025
- Business
- Yahoo
Novo–Hims & Hers deal ends, Eli Lilly GLP-1 pill: What to know
Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of off-brand compounded weight-loss drugs. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Catalysts to explain why Novo pulled out and what it means for the future of Hims & Hers and telehealth in the GLP-1 space. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. shares of hims and hers falling today as Novo Nordisk ends its deal with the telehealth company over concerns that it continues to sell the cheaper off-brand weight loss drugs. Yahoo finance senior health reporter on July Camlani has the latest on this one and and you helped me break this one down before this comes back to the compounds of it all as well here. What more do we know about this decision? Yeah, so this is a surprising move from Novo because they didn't already know that hims was selling the compounded version of its drug, but I think there was some sort of expectation that they were going to either, you know, completely take it off market or slowly take it off market, um, and they haven't done so. They are continuing to sell Semaglutide, which is the chemical compound and active ingredient in Novo Nordisk Wegovy and Ozempic, Wegovy being that weight loss drug that hims had access to directly sell to consumers. That was the agreement a month ago. Now, this has recently come into focus. We know that Eli Lily has been pushing back hard on these telehealth companies as well, um, as well as Medi spas. Both Novo and Lily have been going after anybody that is selling through lawsuits these compounded versions of the drugs. And some compounding pharmacies continue to sell them despite them not being allowed to anymore. They were initially allowed because of the shortage of access to these drugs. Both Lily and Novo struggled to fill the market and so the FDA allowed these compounds on recently taking off and these compounding pharmacies believe that they have a reason to be able to by calling it personalized. And so there's sort of a loophole, if you will, in the FDA rules that allows them to sell personalized drugs, and that's exactly what Novo called out in its comments saying hims and hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of quote unquote personalization. And that's why Novo is no longer working with hims to to give access. Jay, we were talking earlier about the significance of this deal for hims and hers as well as for Novo and trying to get into an audience base that hims and hers has done a very good job of building up over the course of years now. And so now as you think about the pathway forward for hims and hers, how much more difficult does that become, especially with the allegations put forward by Novo? Well, it's definitely a challenge and we're seeing it in stock price. Eli Lily is up, Novo is down on this news as well. Um, to me, that is the big question. What has hims come back and said, I'll ask you, have we have they come out with a statement to, you know, refute this? I've been with Brad so I haven't been able to pay attention what happened over the last hour. Yeah, no, no. We have been in touch with hims and I know we're going to be receiving it soon, but we haven't got one yet. Um, but it is interesting that they do continue to choose to sell the compounded version, uh, because we know that there's so much pressure on them for this reason, as well as the fact that, um, you know, they they already have that agreement with the branded drug company. So it's interesting that they've chosen to continue that tells us pretty much what what we already know, which is the compounded versions are so much cheaper that it creates so much more access. And so what do we know now about the pill format and and some of the advances that companies, biopharmaceutical companies are looking to push forward there? Yeah, what a week for a lot of this news. The American Diabetes Association is meeting this weekend, so that's where all of this GLP1 news is going to be coming out. Um, we have some for you later today as well, but the news this morning we have is that Lily's uh Orforglipron, that is the GLP1 pill, which is potentially the first to market if Novo doesn't beat them to it, um, has no surprises. They have still maintained uh all the data that they have previously exposed, which is, you know, uh good safety tolerability and good weight loss. That weight loss is a little bit lower, I would point out, than what we are used to with those, you know, 20% numbers with the injectables, but it is still promising. They've tested three different uh doses and all looks good there, uh, no surprises from investors. Meanwhile, Wegovy came out with its higher dose, uh, Novador, sorry, came out with a higher dose of Wegovy, 21% weight loss there, and looking at its next gen GLP1 Cagrisema, that's been kind of disappointing to investors, but there's still some looking at potential good news there. Absolutely. On, thanks so much and thanks for getting the pronunciation of Orforglipron correct as well. That's awesome. I've been practicing.
Business Insider
12-05-2025
- Business
- Business Insider
Pharma stocks erase early losses driven by Trump's plans to cut drug prices
Pharma stocks erased their early losses and rallied with the rest of the market on news of a trade deal with China on Monday, despite President Donald Trump announcing plans to bring drug prices down. Eli Lily shares fell by about 3% premarket, while shares of Pfizer and Merck were down more than 2% before rebounding in early trading. On Sunday, Trump announced plans to sign an executive order to bring back the "most favored nation" (MFN) pricing framework. The policy aims to lower US Medicare drug prices to the lowest level paid by other nations in the world. "Prescription Drug and Pharmaceutical prices will be REDUCED, almost immediately, by 30% to 80%," the president wrote in a Truth Social post. MFN was originally introduced by the Trump administration in 2020 and subsequently rolled back by the Biden administration. The MFN policy primarily targets the top 50 Medicare Part B drugs, which includes treatments for cancer and certain vaccines. Americans often pay higher prescription drug prices than citizens of other countries across the world because other countries' healthcare systems can negotiate costs down. For example, countries like the UK and Canada with single-payer systems buy drugs from pharma companies at a low price in exchange for providing access to international markets. Despite Monday's stock-market rally, Trump's executive order would erode pharma companies' pricing power and cut into profits in the long term. "In a grey sky scenario, if it is total exposure across all drugs for each company assuming a 50% net price cut at 60% contribution margin, this would result in a -15% average net income cut," UBS healthcare analysts wrote in a note Monday morning. Eli Lily (LLY): $731, -0.4% Pfizer (PFE): $23, +2% Bristol-Myers Squibb (BMY):$48, +3% Merck (MRK): $79, +4%
